Bristol Myers Squibb Company
NEWS
Evotec entered into a drug discovery collaboration for metabolic diseases with Eli Lilly, focusing on kidney disease and diabetes.
BridgeBio Pharma had inked a non-exclusive clinical partnership with Amgen to study a combination of its BBP-398 with Amgen’s Lumakras in advanced solid tumors with the KRAS G12C mutation.
California-based Dren Bio and Pfizer have partnered on a deal valued at more than $1 billion to discover and develop therapeutic bispecific antibodies for select oncology targets.
The 2022 virtual J.P. Morgan Healthcare Conference got off to a roaring start Monday with deal announcements and plans to drive biopharma companies through the coming year.
BMS and Century Therapeutics agreed to collaborate on the research, development, and commercialization of up to four T cell programs for hematologic malignancies and solid tumors.
The emerging generation of precision gene therapies addresses what has been one of this genre’s greatest challenges to date: the risk of unintended consequences.
ONK announced an infusion of $21.5 million to propel their NK-powered programs towards IND-enabling studies.
Mark Charest, Ph.D., of LifeSci Fund Management, said the J.P. Morgan Healthcare Conference will set the tone for biotech stock performance in 1H 2022.
Going through the most newsworthy stories of the year, BioSpace found trends more than one big story, topics that just kept rising again and again. Here’s a look.
JOBS
IN THE PRESS